« Return to News | CROs/Service Providers

PPD Projects 12% Growth in 2009

Thursday, January 15, 2009 10:48 AM

Wilmington, N.C.-based PPD expects net revenue for 2009 to be in the range of $1.595 to $1.670 billion, a 12% increase over the CRO’s 2008 net revenue forecast. The company projects diluted earnings per share (EPS) for the full year 2009 will be in the range of $1.97 to $2.05, an 18% increase over its full year 2008 EPS forecast.

In October, based on Q3 financial results, the company lowered its full year 2008 revenue projection to between $1.47 billion and $1.49 billion from $1.54 billion to $1.59 billion as a result of an FDA delay in approving diabetes drug alogliptin.

“Our 2009 financial guidance demonstrates our confidence in the core development business, and we plan to continue to focus our efforts on sales execution and operational excellence throughout the year,” PPD CEO Fred Eshelman said in a company release.

PPD announced earlier this week that it has entered into a strategic alliance with World Health Information Science Consultants in order to expand its post-approval drug safety expertise in epidemiology, risk management and pharmacovigilance.

Last week, the company announced a strategic collaboration with Merck that will significantly expand PPD’s global central laboratory business.

“While we enter 2009 facing the stiff headwinds of a global recession, which may affect R&D spending, it is clear that biopharmaceutical companies see strategic partnering as an imperative,” PPD chief operating officer William Sharbaugh told investors in a conference call this morning.

PPD’s shares were down 1.69% to $1.16 in early morning trading.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.